ATE456376T1 - Immortalisierte hepatozyten - Google Patents

Immortalisierte hepatozyten

Info

Publication number
ATE456376T1
ATE456376T1 AT04794437T AT04794437T ATE456376T1 AT E456376 T1 ATE456376 T1 AT E456376T1 AT 04794437 T AT04794437 T AT 04794437T AT 04794437 T AT04794437 T AT 04794437T AT E456376 T1 ATE456376 T1 AT E456376T1
Authority
AT
Austria
Prior art keywords
cell lines
immortalized hepatocytes
immortalized
nontumorigenic
virally
Prior art date
Application number
AT04794437T
Other languages
English (en)
Inventor
Jin Liu
Ronald A Faris
Original Assignee
Multicell Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multicell Technologies Inc filed Critical Multicell Technologies Inc
Application granted granted Critical
Publication of ATE456376T1 publication Critical patent/ATE456376T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT04794437T 2003-10-10 2004-10-07 Immortalisierte hepatozyten ATE456376T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51050903P 2003-10-10 2003-10-10
PCT/US2004/033091 WO2006041488A1 (en) 2003-10-10 2004-10-07 Immortalized hepatocytes

Publications (1)

Publication Number Publication Date
ATE456376T1 true ATE456376T1 (de) 2010-02-15

Family

ID=34435100

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04794437T ATE456376T1 (de) 2003-10-10 2004-10-07 Immortalisierte hepatozyten

Country Status (9)

Country Link
US (2) US7566567B2 (de)
EP (2) EP1685252A4 (de)
JP (2) JP2007518426A (de)
AT (1) ATE456376T1 (de)
AU (1) AU2004280238A1 (de)
CA (2) CA2541380A1 (de)
DE (1) DE602004025380D1 (de)
IL (1) IL174787A0 (de)
WO (2) WO2005034876A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007080990A1 (ja) * 2006-01-12 2007-07-19 Kazuo Ohashi 肝組織細胞機能の長期維持方法
JP5737821B2 (ja) * 2006-08-17 2015-06-17 一夫 大橋 血友病ｂ治療剤及びその製造方法
US8099298B2 (en) * 2007-02-14 2012-01-17 Genelex, Inc Genetic data analysis and database tools
WO2009142767A1 (en) * 2008-05-22 2009-11-26 Lentigen Corporation Lentivector-based protein production
DE112009001245T5 (de) * 2008-05-28 2012-03-15 Basf Se Mittel und Verfahren für die Beurteilung der Leberenzyminduktion
CN101967499A (zh) * 2009-12-09 2011-02-09 河南东都生物科技有限公司 一种还原型辅酶q10的生产方法
US10210312B2 (en) 2013-02-03 2019-02-19 Youscript Inc. Systems and methods for quantification and presentation of medical risk arising from unknown factors
CN103981147B (zh) * 2013-02-08 2017-11-10 中国科学院上海生命科学研究院 一种新的制备肝实质细胞的方法
JP2015008686A (ja) * 2013-06-28 2015-01-19 三菱レイヨン株式会社 肝臓細胞又はその前駆細胞に由来する細胞の状態を評価する方法、並びに、その方法に用いるプローブ又はプローブセット及びマイクロアレイ
JP6418761B2 (ja) * 2014-03-14 2018-11-07 国立大学法人東京工業大学 肝炎組織体、肝炎ウイルスの感染方法、肝炎組織体の製造方法、肝炎ウイルスの増殖方法、肝炎ワクチンの製造方法、スクリーニング方法、及びキット
EP3746137A4 (de) * 2018-01-30 2021-11-24 Capricor, Inc. Für die zelltherapie geeignete aktivierungsinduzierte gewebeeffektorzellen und daraus gewonnene abgeleitete extrazelluläre vesikel
WO2023084648A1 (ja) * 2021-11-10 2023-05-19 株式会社日立ハイテク 薬剤相互作用解析方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS584728A (ja) * 1981-05-01 1983-01-11 メデイカル・リサ−チ・インステイチユ−ト・オブ・サンフランシスコ・コ−ポレ−シヨン α−１−抗トリプシンの精製
US5665589A (en) * 1988-12-14 1997-09-09 The United States Of America As Represented By The Department Of Health And Human Services Human liver epithelial cell lines
US5652097A (en) * 1994-12-14 1997-07-29 Universite De Montreal In vitro test to evaluate the inhibition potency of angiotensin II antagonists on angiotensinogen
US5869243A (en) 1996-03-05 1999-02-09 Rhode Island Hospital Immortalized hepatocytes
BR9708021A (pt) * 1996-03-11 1999-07-27 Bayer Ag Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína
DE19711266C2 (de) 1997-03-05 1999-06-17 Hepavec Ag Fuer Gentherapie Neue humane Leber-Zellinie
EP1002132A4 (de) * 1997-08-05 2005-04-27 Human Genome Sciences Inc Humane sekretierte proteine
US6653105B2 (en) * 1998-02-11 2003-11-25 Vitagen, Inc. Clonal cells and cell lines derived from C3A cells and methods of making and using them
WO1999055853A1 (fr) 1998-04-28 1999-11-04 Takeda Chemical Industries, Ltd. Lignee cellulaire hepatique immortalisee d'origine humaine
AU6162199A (en) 1998-09-25 2000-04-17 Harvard-Mit Division Of Health Science And Technology Reversibly immortalized hepatocytes and methods of use
US6517830B1 (en) * 1999-08-05 2003-02-11 Emory University Compositions and methods for the expression of factor VIII polypeptides and uses therefor
WO2001098493A1 (fr) * 2000-06-15 2001-12-27 Kyowa Hakko Kogyo Co., Ltd Proteine de liaison de facteur de croissance insulinoide
WO2002026942A2 (en) 2000-09-25 2002-04-04 Walter Reed Army Institute Of Research Human liver cell line
CA2447116A1 (en) * 2001-05-17 2002-11-21 Board Of Trustees Of The University Of Illinois Methods for treating liver disease and liver damage with growth hormone and foxm1b

Also Published As

Publication number Publication date
DE602004025380D1 (de) 2010-03-18
AU2004280238A1 (en) 2005-04-21
AU2004280238A2 (en) 2005-04-21
JP2007508019A (ja) 2007-04-05
EP1685252A2 (de) 2006-08-02
EP1704227A4 (de) 2007-01-17
WO2006041488A1 (en) 2006-04-20
US7566567B2 (en) 2009-07-28
EP1704227B1 (de) 2010-01-27
JP2007518426A (ja) 2007-07-12
CA2541380A1 (en) 2005-04-21
WO2006041488A8 (en) 2006-09-08
CA2550452A1 (en) 2006-04-20
WO2005034876A2 (en) 2005-04-21
WO2005034876A3 (en) 2005-10-06
IL174787A0 (en) 2006-08-20
EP1704227A1 (de) 2006-09-27
EP1685252A4 (de) 2006-11-29
US20070004039A1 (en) 2007-01-04
US20070104696A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
IL174787A0 (en) Use of cell lines to produce active therapeutic proteins
MXPA05000858A (es) Metodo de obtener celulas hepaticas humanas viables, incluyendo celulas hepaticas troncales/progenitoras.
GB2453068A (en) Novel hepatocyte-like cells and hepatoblast-like cells derived from hbs cells
DK1682537T3 (da) Modulatorer af celleadhæsion
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
IS8214A (is) 3,5 tvísetin indasól enfasambönd, lyfjasamsetningar, og aðferðir til að miðla eða hindra frumufjölgun
TW200716647A (en) Synthesis of (R)-N-methylnaltrexone
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
DK1299348T3 (da) Forbindelser og sammensætninger til levering af aktive midler
EA200800542A1 (ru) Пиридинаминосульфонилзамещенные бензамиды в качестве ингибиторов цитохрома р450 3а4 (cyp3a4)
SG153800A1 (en) Pharmaceutical compositions
WO2007002385A3 (en) Mesoderm and definitive endoderm cell populations
DE602005024274D1 (de) Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
NO20070073L (no) Pyrazolderivater, preparater inneholdende disse og metoder for anvendelse derav
NO20074179L (no) Prodrugs av 2,4-pyrimidindiaminforbindelser og deres anvendelse
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
CY1110337T1 (el) Παρασκευη πρεγκαμπαλινης και σχετικων ενωσεων
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
TW200714590A (en) Heterocyclic inhibitors of MEK and methods of use thereof
SE0301700D0 (sv) Novel compounds
NO20091299L (no) Substituerte sulfonamidderivater
MXPA05011522A (es) Derivados de 2-acilamino-4-feniltiazol, metodo para su preparacion y su aplicacion en terapeutica.
IS2799B (is) Kladribínefnablöndur til inngjafar um munn
TW200738649A (en) Calcilytic compounds
TW200602062A (en) Improved formulations of 6-mercaptopurine

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties